The transdermal revolution.
Historically, developments in transdermal drug delivery have been incremental, focusing on overcoming problems associated with the barrier properties of the skin, reducing skin irritation rates and improving the aesthetics associated with passive patch systems. More-recent advances have concentrated on the development of non-passive systems to aid delivery of larger drug molecules, such as proteins and nucleotides, as the trend for discovering and designing biopharmaceuticals continues. Fundamentally, improvements in transdermal delivery will remain incremental until there is wider acceptance of this route of administration within the pharmaceutical industry. Only then will the transdermal revolution live up to its true potential.
Thomas
Beverley J
BJ
Acrux Limited, 103-113 Stanley Street, West Melbourne, Victoria 3003, Australia.
Finnin
Barrie C
BC
D000279:Administration, Cutaneous; D000818:Animals; D055598:Chemical Phenomena; D002626:Chemistry, Pharmaceutical; D002627:Chemistry, Physical; D016503:Drug Delivery Systems; D006801:Humans; D004364:Pharmaceutical Preparations / Q000008:administration & dosage* / Q000737:chemistry; D012869:Skin Absorption; D012879:Skin Physiological Phenomena; D013678:Technology, Pharmaceutical
D004364:Pharmaceutical Preparations